Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with BRCA2 mutations, which are also linked to hereditary breast cancer, ovarian cancer, and pancreas cancer, among others. The finding was confirmed in a study, led by Elena Castro, MD, PhD, Nuria Romero-Laorden, MD, PhD, and David Olmos, MD, PhD, from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) in Madrid (J Clin Oncol 2019; doi:10.1200/JCO.18.00358). It reveals that family members of patients with prostate cancer who carry BRCA2 and DNA-repair gene mutations have an increased risk of developing cancer and should be evaluated in familial cancer prevention programs.
Furthermore, the new study shows that prostate cancer in men with BRCA2 mutations is associated with worse outcomes and poor responses to standard treatments. Researchers are currently assessing the benefits of ovarian and breast cancer therapies for prostate cancer patients.
The recently published article reports the first results of PROREPAIR-B, a study coordinated by CNIO researchers and conducted at the Instituto de Investigacion Biomedica de Malaga and the Instituto de Genetica Medica y Molecular, with the participation of 38 Spanish hospitals. More than 400 men diagnosed with prostate cancer resistant to castration—or hormone blockade—were followed up for 5 years starting in 2013 to analyze their genetic characteristics and the impact of these on the progression of the disease and response to treatments.
“This is the first prospective study—that is not looking back in time but watching for outcomes from the moment patients are diagnosed with advanced cancer—that shows BRCA2 mutations themselves, regardless of other factors, are responsible for poor prognosis and can have an impact on treatment responses,” explained Castro, the article's first author.
“It should be noted that we identified germline mutations, although in a number of patients there were no familial cancer cases that might have indicated the presence of such genetic alterations. These mutations should be identified in patients with metastatic prostate cancer, since detecting such alterations is important for the diagnosis and management of the disease and for the patients' families, whose risk of developing breast, ovarian, or pancreatic cancer is increased,” Castro noted.
PROREPAIR-B is the first prospective cohort study carried out for a long period that involves a large number of patients diagnosed with metastatic prostate cancer castration resistant and with hereditary alterations.
“Our study shows that treatment and follow-up protocols used in patients with advanced prostate cancer may be inadequate for men with BRCA2 mutations. We are currently studying the characteristics that make these tumors more aggressive and trying to establish new strategies to improve patient prognosis,” said David Olmos, Head of the CNIO Prostate Cancer Clinical Research Unit and coordinator of the project.
Prostate cancer is the most frequent cancer among males in Spain and Western countries, and the second most frequent worldwide. Most tumors are detected early, which improves prognosis. Advanced prostate cancer is usually treated with hormone therapy; however, a number of patients develop castration-resistant prostate cancer. Some of these patients show poor responses to standard treatments. In general, survival in patients with resistance to androgen deprivation therapy is 3 years on average.
One of the main goals of PROREPAIR-B is to identify genetic markers associated to poor prognosis. In addition, understanding the genetic traits of aggressive tumors can help to explore novel treatment pathways.
The study focuses mainly on genetic patterns associated to deficiencies in DNA-repair mechanisms. Tumor cells carry many more genetic alterations than normal cells, which means they need highly effective repair mechanisms. According to Castro, the research team “knew DNA repair is extremely important in prostate cancer. What we did not know was the proportion of patients in the population with advanced stage disease and hereditary mutations.”
The study shows that 3 percent of the patients carry BRCA2 mutations, a percentage that reaches 16 percent when all DNA-repair genes are considered. “This proportion may seem comparatively low but it comprises a significant number of patients, given the high incidence of prostate cancer,” Castro noted.
The researchers who participated in the study believe treatment strategies should be improved by optimizing existing therapies and finding new drugs. In some patients, drugs interfering with DNA-repair mechanisms might be effective, as the cells that cannot repair their genetic defects die.
These drugs are PARP inhibitors, which have been approved for ovarian cancer and whose efficiency in prostate cancer is currently being tested in a number of clinical trials. Carboplatin is another drug that is currently being used to treat breast and ovarian cancers.
Have Stories Delivered Directly to You
Sign up for our free e-newsletter and receive email notifications when each issue becomes available and when other new content is posted online. New to Oncology Times? Visit the publication's website at www.oncology-times.com where you can get free access to archived issues, subscribe to the print magazine, and create your own personal online article collections.